单位：[1]The Woolcock Institute of Medical Research and The University of Sydney, Sydney, Australia[2]Monroe Carell Jr.Children’s Hospital atVanderbilt, Vanderbilt University Medical Center, Nashville, TN, USA[3]Dept of Medicine, University of Cape Town, Cape Town, SouthAfrica[4]Leicester National Institute for Health Research Biomedical Research Centre, University of Leicester, Leicester, UK[5]Dept ofRespiratory Medicine, Ghent University Hospital, Ghent, Belgium[6]Depts of Epidemiology and Respiratory Medicine, Erasmus MedicalCenter, University Medical Center Rotterdam, Rotterdam, The Netherlands[7]Pulmonary Dept, Mainz University Hospital, Mainz,Germany[8]Federal University of Bahia, Salvador, Brazil[9]Dept of Pediatrics, Erasmus Medical Center, University Medical CenterRotterdam, Rotterdam, The Netherlands[10]Divisions of Medical Communication and Pulmonary Medicine, Dept of Medicine, Brighamand Women’s Hospital, Boston, MA, USA[11]Harvard Medical School, Boston, MA, USA[12]University of British Columbia, Vancouver, BC,Canada[13]Imperial College London, London, UK[14]Kagoshima University, Kagoshima, Japan[15]The Chinese University of Hong Kong,Hong Kong[16]Breathe Chicago Center, University of Illinois Chicago, Chicago, IL, USA[17]Locum General Practitioner, London, UK[18]China–Japan Friendship Hospital, Peking University, Beijing, China[19]Dept of Respiratory Medicine, Liverpool University HospitalsNational Health Service Foundation Trust, Liverpool, UK[20]Dept of Medicine, University of Cambridge, Cambridge, UK[21]PediatricRespiratory Division, Hospital Moinhos de Vento, Porto Alegre, Brazil[22]Usher Institute, University of Edinburgh, Edinburgh, UK[23]Deptof Pulmonology, Celal Bayar University, Manisa, Turkey[24]Institut universitaire de cardiologie et de pneumologie de Québec, QC,Canada[25]Département de médecine, Université Laval, Québec, QC, Canada
The Global initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g. medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not he treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >= 60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, "MART") in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.
第一作者单位：[1]The Woolcock Institute of Medical Research and The University of Sydney, Sydney, Australia
通讯作者：
推荐引用方式(GB/T 7714)：
Helen K. Reddel,Leonard B. Bacharier,Eric D. Bateman,et al.Global initiative for Asthma Strategy 2021: executive summary and rationale for key changes[J].EUROPEAN RESPIRATORY JOURNAL.2022,59(1):doi:10.1183/13993003.02730-2021.
APA：
Helen K. Reddel,Leonard B. Bacharier,Eric D. Bateman,Christopher E. Brightling,Guy G. Brusselle...&Louis-Philippe Boulet.(2022).Global initiative for Asthma Strategy 2021: executive summary and rationale for key changes.EUROPEAN RESPIRATORY JOURNAL,59,(1)
MLA：
Helen K. Reddel,et al."Global initiative for Asthma Strategy 2021: executive summary and rationale for key changes".EUROPEAN RESPIRATORY JOURNAL 59..1(2022)
医学